Developer docs
API playgroundTry for free, no card

Search company profiles

Brinter

Full company profile

uuid0002ef2

Namestring
Brinter
Legal namestring
Brinter, Inc.
Websiteurl
brinter.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Brinter, Inc. is a US-incorporated medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair and adjacent applications. Founded in Turku, Finland in 2018 by Tomi Alapaattikoski and Tomi Kalpio, the company relocated its headquarters to Santa Monica, California in 2021 after completing its core platform and securing a €1.2M seed round led by Innovestor. The company's foundation is a proprietary medical-grade multi-material 3D bioprinting platform developed over more than eight years and protected by 10 patents; the platform can print any material, viscosity, and temperature in a single construct and supports closed-loop manufacturing from raw material preparation through final sterilization. Brinter holds this platform exclusively for its own implant portfolio and does not sell or license the technology.

The company's commercial focus is its lead BioMod rotator cuff implant — a bioinductive augmented implant for tissue reinforcement targeting a Q1/2028 US launch and claimed to deliver 3X the strength, 26% better regenerative structure, and 68% fewer failures versus suture-only repair. Beyond the lead product, Brinter is building a pipeline spanning breast reconstruction, ACL, Achilles, meniscus, articular cartilage, nasal, genital, limb, and spinal disc implants across orthopedic, aesthetic, and reconstructive surgery verticals. All products are investigational devices that have not been approved for commercial use in any country. Distribution is planned through direct enterprise engagement with surgeons and medical institutions, supported by a Surgeon Advisory Board of seven named key opinion leaders.

Revenue mechanics are not yet in place: the company is pre-commercial, pricing is not publicly disclosed, and total disclosed capital stands at roughly $4.5M of equity investment plus $6.5M in grants. Strategic partnerships with the Wake Forest Institute for Regenerative Medicine (since 2022), Techstars (2024 graduate), and Plug and Play (2025 graduate), together with TIME Magazine Best Inventions 2025 recognition, anchor credibility as the company prepares its FDA regulatory pathway.

Short descriptiontext

Brinter is a US medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair, using a proprietary multi-material bioprinting platform. Its lead BioMod rotator cuff implant is investigational and targeted for Q1/2028 US commercial launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSanta Monica, United States
HQ citystring
Santa Monica
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bioprinting, regenerative implants, orthopedic devices, tissue engineering, medical device manufacturing
Industry4 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Medical Implants
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Regenerative Implant Sales
TypeOne Time License
Description

Brinter is approaching commercialization of the first-ever 3D bioprinted regenerative implant in the United States. The company manufactures medical-grade implants for orthopedic and aesthetic applications. Their implants are investigational devices not yet approved for commercial use in any country.

brinter.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Brinter develops and manufactures 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair using its proprietary medical-grade multi-material 3D bioprinting platform. Its flagship product, the BioMod Rotator Cuff Implant, is approaching commercialization with a Q1/2028 target launch, alongside a pipeline of additional orthopedic, aesthetic, and other regenerative implants currently investigational.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 3X stronger vs suture-only repair
+2 more records
Product overview1 text field

Brinter offers a proprietary medical-grade 3D bioprinting platform that serves as the core technology for its portfolio of regenerative implants. The platform enables multi-material bioprinting of customizable, bioabsorbable implants tailored for medical applications. The product line includes the BioMod Rotator Cuff Implant (launching Q1/2028), Breast Implant, and additional orthopedic implants (ACL, Achilles, Meniscus, Articular Cartilage) in various pipeline stages, as well as R&D implants (Nasal, Genital, Limb, Spinal Disc). The company maintains closed-loop manufacturing control from raw material preparation through final sterilization, producing investigational devices not yet approved for commercial use.

Product and service6 records
1BioMod Rotator Cuff Implant
CategoryOrthopedic Regenerative Implants
Description

Bioinductive augmented implant for rotator cuff reinforcement that supports healing, promotes tissue regeneration, and provides strength; reported to be 3X stronger, deliver 26% better regenerative structure, and achieve 68% fewer failures versus suture-only repair. For orthopedic surgeons and their patients with rotator cuff injuries.

2Breast Implant
CategoryAesthetic and Reconstructive Implants
Description

3D bioprinted regenerative breast implant designed to restore natural shape, softness, and tissue integration following mastectomy. For reconstructive surgeons and post-mastectomy patients.

3ACL Implant
CategoryOrthopedic Regenerative Implants
Description

Regenerative 3D bioprinted implant for anterior cruciate ligament repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring ACL reconstruction.

4Achilles Implant
CategoryOrthopedic Regenerative Implants
Description

Regenerative 3D bioprinted implant for Achilles tendon repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring Achilles repair.

5Meniscus Implant
CategoryOrthopedic Regenerative Implants
Description

Regenerative 3D bioprinted implant for meniscus repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring meniscus treatment.

6Articular Cartilage Implant
CategoryOrthopedic Regenerative Implants
Description

Regenerative 3D bioprinted implant for articular cartilage repair within the orthopedic pipeline. For orthopedic surgeons and patients requiring articular cartilage restoration.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership established in 2022 for collaboration on regenerative medicine research and development. The partnership leverages Wake Forest's expertise in regenerative medicine alongside Brinter's bioprinting technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Accelerator program graduate in 2024, providing mentorship, networking, and startup support services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Accelerator program graduate in 2025, providing access to innovation ecosystem and corporate partnerships.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arthrex is the dominant private orthopedic sports medicine company with deep portfolios in rotator cuff, ACL, meniscus, and Achilles repair, the exact indications Brinter's BioMod and pipeline products target. Arthrex is the primary incumbent Brinter must displace in surgeon adoption.

TypeBroad incumbent
Description

Smith+Nephew operates a large sports medicine and orthopedic repair franchise (including REGENETEN bioinductive implants for rotator cuff) that directly competes with Brinter's BioMod and adjacent pipeline. Comparable as a broad incumbent entering the regenerative orthopedic implant space.

TypeBroad incumbent
Description

Stryker's orthopedic and sports medicine divisions serve the same surgeons and institutions that Brinter targets, with the capital and M&A capacity to acquire or build competing regenerative technologies. Comparable as a broad orthopedic incumbent.

TypeDirect peer
Description

BICO, parent of Cellink, is the closest direct peer in 3D bioprinting hardware and consumables for life sciences and medical applications. Comparable as a bioprinting platform company that also pursues regenerative medicine applications.

5Aspect Biosystems
TypeDirect peer
Description

Aspect Biosystems develops microfluidic 3D bioprinting technology for regenerative medicine and tissue engineering, including implantable therapeutic tissues. Directly comparable as a peer bioprinting company pursuing regenerative medical applications.

TypeDirect peer
Description

Organovo was a pioneer in 3D bioprinted human tissues for medical research and therapeutic applications. Comparable as a historical direct peer in 3D bioprinting for medical/regenerative use, though now operating at much smaller scale.

TypeBroad incumbent
Description

Integra LifeSciences has a meaningful regenerative medicine and tissue engineering franchise (e.g., dermal regeneration, dural repair) that overlaps with Brinter's regenerative implant thesis. Comparable as a broad incumbent in regenerative implants.

TypeBroad incumbent
Description

CONMED's sports medicine portfolio covers rotator cuff, meniscus, and ACL repair instrumentation and implants. Comparable as a broad orthopedic sports medicine incumbent competing for the same surgical accounts.

TypeEmerging player
Description

Vericel commercializes cell therapy and regenerative medicine products (MACI for cartilage repair) and is a relevant comparable as a smaller, commercially focused regenerative medicine company targeting similar orthopedic indications.

TypeEmerging player
Description

MiMedx develops placental tissue allografts for soft-tissue repair, including applications overlapping with rotator cuff and other orthopedic sports medicine indications. Comparable as an emerging regenerative soft-tissue repair peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brinter

Regenerative Medical Implantsbrinter.com

Brinter is a US medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair, using a proprietary multi-material bioprinting platform. Its lead BioMod rotator cuff implant is investigational and targeted for Q1/2028 US commercial launch.

What Brinter does

Brinter, Inc. is a US-incorporated medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair and adjacent applications. Founded in Turku, Finland in 2018 by Tomi Alapaattikoski and Tomi Kalpio, the company relocated its headquarters to Santa Monica, California in 2021 after completing its core platform and securing a €1.2M seed round led by Innovestor. The company's foundation is a proprietary medical-grade multi-material 3D bioprinting platform developed over more than eight years and protected by 10 patents; the platform can print any material, viscosity, and temperature in a single construct and supports closed-loop manufacturing from raw material preparation through final sterilization. Brinter holds this platform exclusively for its own implant portfolio and does not sell or license the technology.

The company's commercial focus is its lead BioMod rotator cuff implant — a bioinductive augmented implant for tissue reinforcement targeting a Q1/2028 US launch and claimed to deliver 3X the strength, 26% better regenerative structure, and 68% fewer failures versus suture-only repair. Beyond the lead product, Brinter is building a pipeline spanning breast reconstruction, ACL, Achilles, meniscus, articular cartilage, nasal, genital, limb, and spinal disc implants across orthopedic, aesthetic, and reconstructive surgery verticals. All products are investigational devices that have not been approved for commercial use in any country. Distribution is planned through direct enterprise engagement with surgeons and medical institutions, supported by a Surgeon Advisory Board of seven named key opinion leaders.

Revenue mechanics are not yet in place: the company is pre-commercial, pricing is not publicly disclosed, and total disclosed capital stands at roughly $4.5M of equity investment plus $6.5M in grants. Strategic partnerships with the Wake Forest Institute for Regenerative Medicine (since 2022), Techstars (2024 graduate), and Plug and Play (2025 graduate), together with TIME Magazine Best Inventions 2025 recognition, anchor credibility as the company prepares its FDA regulatory pathway.

Brinter firmographics

Firmographics
Name
Brinter
Legal name
Brinter, Inc.
Website
https://brinter.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Brinter is a US medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair, using a proprietary multi-material bioprinting platform. Its lead BioMod rotator cuff implant is investigational and targeted for Q1/2028 US commercial launch.
Ownership category
akta.pro rank

Brinter industry classification

Industry
Product category
Regenerative Medical Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • 3D bioprinting
  • Regenerative implants
  • Orthopedic devices
  • Tissue engineering
  • Medical device manufacturing

Where Brinter is headquartered

Location

Headquarters

HQ city
Santa Monica
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Brinter business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Regenerative Implant Sales: Brinter is approaching commercialization of the first-ever 3D bioprinted regenerative implant in the United States. The company manufactures medical-grade implants for orthopedic and aesthetic applications. Their implants are investigational devices not yet approved for commercial use in any country.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Brinter product offering

Product offering

Core offering

Brinter develops and manufactures 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair using its proprietary medical-grade multi-material 3D bioprinting platform. Its flagship product, the BioMod Rotator Cuff Implant, is approaching commercialization with a Q1/2028 target launch, alongside a pipeline of additional orthopedic, aesthetic, and other regenerative implants currently investigational.

Product overview

Brinter offers a proprietary medical-grade 3D bioprinting platform that serves as the core technology for its portfolio of regenerative implants. The platform enables multi-material bioprinting of customizable, bioabsorbable implants tailored for medical applications. The product line includes the BioMod Rotator Cuff Implant (launching Q1/2028), Breast Implant, and additional orthopedic implants (ACL, Achilles, Meniscus, Articular Cartilage) in various pipeline stages, as well as R&D implants (Nasal, Genital, Limb, Spinal Disc). The company maintains closed-loop manufacturing control from raw material preparation through final sterilization, producing investigational devices not yet approved for commercial use.

Differentiator

Problem solved

Functional benefit

Products and services

  • BioMod Rotator Cuff Implant Bioinductive augmented implant for rotator cuff reinforcement that supports healing, promotes tissue regeneration, and provides strength; reported to be 3X stronger, deliver 26% better regenerative structure, and achieve 68% fewer failures versus suture-only repair. For orthopedic surgeons and their patients with rotator cuff injuries.
  • Breast Implant 3D bioprinted regenerative breast implant designed to restore natural shape, softness, and tissue integration following mastectomy. For reconstructive surgeons and post-mastectomy patients.
  • ACL Implant Regenerative 3D bioprinted implant for anterior cruciate ligament repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring ACL reconstruction.
  • Achilles Implant Regenerative 3D bioprinted implant for Achilles tendon repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring Achilles repair.
  • Meniscus Implant Regenerative 3D bioprinted implant for meniscus repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring meniscus treatment.
  • Articular Cartilage Implant Regenerative 3D bioprinted implant for articular cartilage repair within the orthopedic pipeline. For orthopedic surgeons and patients requiring articular cartilage restoration.

Quantifiable outcome

  • 3X stronger vs suture-only repair
  • +2 more outcomes

Companies that use Brinter

Customer profile

Segments3 records

Ideal customer profiles3 records

Brinter technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Brinter partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Wake Forest Institute for Regenerative MedicinecoreStrategic or Co-development PartnerStrategic partnership established in 2022 for collaboration on regenerative medicine research and development. The partnership leverages Wake Forest's expertise in regenerative medicine alongside Brinter's bioprinting technology.
  • TechstarsminorStrategic or Co-development PartnerAccelerator program graduate in 2024, providing mentorship, networking, and startup support services.
  • Plug and PlayminorStrategic or Co-development PartnerAccelerator program graduate in 2025, providing access to innovation ecosystem and corporate partnerships.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Brinter competitors and assessment

Company assessment

Direct peers

  • Arthrex: Arthrex is the dominant private orthopedic sports medicine company with deep portfolios in rotator cuff, ACL, meniscus, and Achilles repair, the exact indications Brinter's BioMod and pipeline products target. Arthrex is the primary incumbent Brinter must displace in surgeon adoption.
  • BICO (Cellink): BICO, parent of Cellink, is the closest direct peer in 3D bioprinting hardware and consumables for life sciences and medical applications. Comparable as a bioprinting platform company that also pursues regenerative medicine applications.
  • Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting technology for regenerative medicine and tissue engineering, including implantable therapeutic tissues. Directly comparable as a peer bioprinting company pursuing regenerative medical applications.
  • Organovo: Organovo was a pioneer in 3D bioprinted human tissues for medical research and therapeutic applications. Comparable as a historical direct peer in 3D bioprinting for medical/regenerative use, though now operating at much smaller scale.

Broad incumbents

  • Smith+Nephew: Smith+Nephew operates a large sports medicine and orthopedic repair franchise (including REGENETEN bioinductive implants for rotator cuff) that directly competes with Brinter's BioMod and adjacent pipeline. Comparable as a broad incumbent entering the regenerative orthopedic implant space.
  • Stryker: Stryker's orthopedic and sports medicine divisions serve the same surgeons and institutions that Brinter targets, with the capital and M&A capacity to acquire or build competing regenerative technologies. Comparable as a broad orthopedic incumbent.
  • Integra LifeSciences: Integra LifeSciences has a meaningful regenerative medicine and tissue engineering franchise (e.g., dermal regeneration, dural repair) that overlaps with Brinter's regenerative implant thesis. Comparable as a broad incumbent in regenerative implants.
  • CONMED: CONMED's sports medicine portfolio covers rotator cuff, meniscus, and ACL repair instrumentation and implants. Comparable as a broad orthopedic sports medicine incumbent competing for the same surgical accounts.

Emerging players

  • Vericel: Vericel commercializes cell therapy and regenerative medicine products (MACI for cartilage repair) and is a relevant comparable as a smaller, commercially focused regenerative medicine company targeting similar orthopedic indications.
  • MiMedx: MiMedx develops placental tissue allografts for soft-tissue repair, including applications overlapping with rotator cuff and other orthopedic sports medicine indications. Comparable as an emerging regenerative soft-tissue repair peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Brinter social profiles

Digital presence

Brinter financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brinter leadership team

Management profile

Number of profiles

Profiles3 records

Brinter subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Brinter funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brinter M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brinter

What does Brinter do?

Brinter develops and manufactures 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair using its proprietary medical-grade multi-material 3D bioprinting platform. Its flagship product, the BioMod Rotator Cuff Implant, is approaching commercialization with a Q1/2028 target launch, alongside a pipeline of additional orthopedic, aesthetic, and other regenerative implants currently investigational.

Is Brinter a public or private company?

Brinter is a private company. It is classified as venture growth investor backed and is currently operating.

When was Brinter founded?

Brinter was founded in 2018. It employs 1 to 10 people.

Where is Brinter based?

Brinter is headquartered in Santa Monica, United States, in the North America region.

How does Brinter make money?

One revenue line is on record: regenerative Implant Sales.

Who are Brinter's main competitors?

Direct peers on record are Arthrex, BICO (Cellink), Aspect Biosystems and Organovo. Broad incumbents are Smith+Nephew, Stryker, Integra LifeSciences and CONMED. Emerging players are Vericel and MiMedx.

Does Brinter have an API?

No public API is recorded for Brinter.

What industry is Brinter in?

Brinter's product category is Regenerative Medical Implants. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GreyBTop 5 3D Bioprinting Startups to Watch in 2025This article profiles five early-stage 3D bioprinting startups with growth potential in 2025: 4D Biomaterials (UK, $2.1M funding), Next Big Innovation Labs (India, developing 3D bioprinted human skin), SPEBIO (South Korea, cell aggregation platform), Brinter (USA, $2.2M funding, bioprinted implants), and VoxCell BioInnovation (Canada, $1.7M funding, vascularized cancer tissue models). The startups collectively aim to address challenges in drug development, organ transplantation, and personalized medicine through innovations in 3D bioprinting technology.American City Business JournalsThree Strands Recovery Wear, Brinter and Deep Creek Pharma vie for $60,000 from NC Biotech’s 2024 Venture ChallengeThree Triad startups—Three Strands Recovery Wear, Brinter, and Deep Creek Pharma—were named finalists in NC Biotech's 2024 Venture Challenge, competing for up to $60,000. The challenge offers $20,000 to each regional winner and $200,000 in grants and mentoring, with a pitch competition on June 27.American City Business JournalsFinnish 3D bioprinting startup Brinter to make Winston-Salem its headquartersBrinter, a Finnish 3D bioprinting startup, will make Winston-Salem its headquarters to advance cartilage-based bioimplants. The company plans to double its headcount, begin clinical trials next year, and raise a $6–9 million Series A. It aims for human trials in 2025 and commercialization by 2028.ElinextExploring Bioprinting SoftwareThis article provides an overview of the bioprinting software market, projecting growth to USD 5.1-5.3 billion by 2030 with a CAGR of 12.5-15.4%, driven by AI-based path planning, cloud collaboration, and medical imaging integration that reportedly reduces printing errors by 30%. It profiles key bioprinting companies across the United States—including Organovo, Allevi, TeVido, Brinter, and CELLINK—and Germany—Cellbricks, MEDPRIN, Black Drop Biodrucker, and INNOTERE—highlighting that the US leads innovation while Germany drives Europe's market expansion expected to reach $649.91 million by 2027. The article emphasizes that advancements in bioprinting software are enabling more precise patient-specific tissue engineering, personalized medicine, and pharmaceutical research applications.BrinterHP Multi Jet Fusion technology helps Brinter launch its innovative bioprinting solutions faster and more affordablyBrinter, a Finnish bioprinting company, adopted HP Multi Jet Fusion technology through its partner 3DTech to manufacture over 60 3D-printed parts comprising 75% of the custom medical equipment in its Brinter Bioprinter. The parts are tested within days rather than weeks or months, reducing supply risk and cost. Future applications may include clinical bioprinting treatments.news.cision.comBrinter launches new medical printing heads with Puredyne to enable nearly zero dead volume and cut wasteBrinter announced new extrusion-based Visco Bio print heads for its bioprinters, developed with Puredyne. The heads enable nearly zero dead volume, reducing waste and allowing material diversity with single cartridges per material. The company also recently launched its entry-level Brinter Core model.Innovestor3D bioprinting from personalized drugs to human spare partsTurku-based bioprinting startup Brinter has closed a €1.2M seed funding round led by venture capital firm Innovestor to expand its operations internationally in Europe and the US. The company utilizes modular multi-material 3D bioprinting technology to assist pharmaceutical companies, hospitals, and research centers in drug discovery and the potential production of personalized biological spare parts.FinSMEsBrinter Raises €1.2M in Seed FundingBrinter, a bioprinting startup based in Turku, Finland, has closed a €1.2 million seed funding round led by early-stage VC Innovestor. The company intends to use the capital to expand its operations internationally across Europe and the US. Founded in 2020, Brinter provides modular multi-material bioprinting platforms for science and bioengineering organizations.Nordic 9Brinter raised €1.2M in a seed funding round led by early-stage VC Innovestor.Brinter, a Finnish 3D bioprinting platform developer, raised €1.2M in seed funding led by Innovestor. The funds will support its bioprinting platform for pharmaceutical, biotech, and cosmetic industries. Customers include Nanoform, VTT, and several universities.